Prevention
of Lyme Disease Through Active Immunization:
Recommendations
of the Advisory Committee on Immunization Practices (ACIP)
Summary
This report provides recommendations for use of a newly developed
recombinant outer-surface protein A (Osp A) Lyme disease vaccine
(LYMErix™, SmithKline Beecham Pharmaceuticals) in persons
15 years of age and older within the United States. The purpose
of these recommendations is to provide healthcare providers,
public health authorities, and the public with guidance on the
risk of acquiring Lyme disease and on the role of vaccine as
an adjunct to preventing Lyme disease. The Committee recommends
that decisions regarding vaccine use be based on assessment of
individual risk, taking into account both geographical risk and
a personÕs activities and behaviors relating to tick exposure.
